Changchun University of Chinese Medicine, Changchun, People's Republic of China.
The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, People's Republic of China.
Medicine (Baltimore). 2022 Dec 16;101(50):e32182. doi: 10.1097/MD.0000000000032182.
To provide evidence, this review evaluated the methodological quality, risk of bias, and reporting quality of SRs/MAs in the treatment of Facial Spasm with acupuncture.
Systematic reviews and Meta analyses (SRs/MAs) of acupuncture for Facial Spasm were retrieved from 8 databases from inception to October 1, 2022. Two reviewers independently screened the literature and extracted the data, then used Assessment of Multiple Systematic Reviews-2 (AMSTAR-2), Bias Risk in Systematic Review (ROBIS), and Preferred Report Item for Systematic review and Meta-analysis (PRISMA), Grading of Recommendations, Assessment, Development and Evaluation (GRADE) to assess methodological quality, risk of bias, quality of reporting, and quality of evidence.
A total of 8 SRs/meta-analyses were included. All the SRs were published between 2012-2022. Based on AMSTAR-2, 8 SRs were rated critically low quality. By using the ROBIS tool, 6 SRs were rated low-risk bias. With the PRISMA-A checklist, we found 2 out of 8 SRs were found adequately reported over 70%. With the GRADE system, no high-quality evidence was found, and only two outcomes provided moderate-quality evidence. Among the downgraded factors, the risk of bias within the original trials was ranked first, followed by publication bias, inconsistency, and imprecision.
Acupuncture is a promising complementary treatment for HFS. However, due to the low quality of the SRs/MAs supporting these results, high-quality studies with rigorous study designs and larger samples are needed before widespread recommendations can be made.
为提供证据，本综述评估了针刺治疗面肌痉挛的系统评价/荟萃分析（SRs/MAs）的方法学质量、偏倚风险和报告质量。
从 8 个数据库中检索到截至 2022 年 10 月 1 日针刺治疗面肌痉挛的系统评价和荟萃分析。两名评审员独立筛选文献并提取数据，然后使用评估多个系统评价-2（AMSTAR-2）、系统评价偏倚风险（ROBIS）、系统评价和荟萃分析首选报告项目（PRISMA）、推荐分级评估、制定与评价（GRADE）评估方法学质量、偏倚风险、报告质量和证据质量。
共纳入 8 项 SRs/meta 分析。所有的 SR 都发表于 2012-2022 年之间。根据 AMSTAR-2，8 项 SR 被评为严重低质量。使用 ROBIS 工具，6 项 SR 被评为低风险偏倚。根据 PRISMA-A 清单，我们发现 8 项 SR 中有 2 项在 70%以上的项目上报告充分。使用 GRADE 系统，没有发现高质量的证据，只有两个结局提供了中等质量的证据。在降级因素中，原始试验的偏倚风险排名第一，其次是发表偏倚、不一致性和不精确性。
针刺是治疗 HFS 的一种有前途的补充疗法。然而，由于支持这些结果的 SRs/MAs 质量较低，需要进行高质量的研究，设计严谨，样本量更大，然后才能提出广泛的建议。
